{"id":"ot-101-ophthalmic-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation"},{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Eye discomfort"}]},"_chembl":{"chemblId":"CHEMBL2108251","moleculeType":"Oligosaccharide"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"OT-101 targets the Wnt signaling pathway, which plays a key role in pathological corneal neovascularization and fibrosis. By inhibiting this pathway, the drug aims to suppress abnormal blood vessel growth and reduce inflammatory responses in corneal diseases. This mechanism is particularly relevant for conditions characterized by corneal scarring and vision loss due to neovascularization.","oneSentence":"OT-101 is a small-molecule inhibitor of the Wnt/β-catenin signaling pathway designed to reduce corneal neovascularization and inflammation in the eye.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:50:46.771Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Corneal neovascularization and scarring"},{"name":"Alkali burn of the eye"}]},"trialDetails":[{"nctId":"NCT04770610","phase":"PHASE3","title":"Study of OT-101 in Treating Myopia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ocumension (Hong Kong) Limited","startDate":"2021-04-01","conditions":"Myopia, Progressive","enrollment":678}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Investigational Product"],"phase":"phase_3","status":"active","brandName":"OT-101 Ophthalmic Solution","genericName":"OT-101 Ophthalmic Solution","companyName":"Ocumension (Hong Kong) Limited","companyId":"ocumension-hong-kong-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"OT-101 is a small-molecule inhibitor of the Wnt/β-catenin signaling pathway designed to reduce corneal neovascularization and inflammation in the eye. Used for Corneal neovascularization and scarring, Alkali burn of the eye.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}